Carol Touma
Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1659597466
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AbbVie at 49.0% of the total. Reporting peaked in 2023 at $2,370 and has fallen 84.6% since, to $364 in 2025.
Across 85 payments — averaging $55.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Tandem Diabetes Care, Inc.$330
- Novo Nordisk$310
- Sanofi-aventis U.S. LLC$266
- Lilly USA, LLC$256
- Insulet Corporation$214
- plus $1K from 17 others
What the payments were for
- Consulting fees$2,25048%
- Speaking & faculty fees$3006%
- Food & beverage$2,17046%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $2,320 |
| Tandem Diabetes Care, Inc. | 3 | $330 |
| Novo Nordisk | 17 | $310 |
| Sanofi-aventis U.S. LLC | 4 | $266 |
| Lilly USA, LLC | 20 | $256 |
| Insulet Corporation | 2 | $214 |
| Medtronic | 1 | $157 |
| Dexcom, Inc. | 6 | $142 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Abbott | 1 | $124 |
| BETA Bionics, Inc. | 1 | $73 |
| AstraZeneca | 4 | $55 |
| Johnson & Johnson | 4 | $50 |
| Amarin Pharma, Inc. | 3 | $44 |
| Corcept Therapeutics | 2 | $31 |
| Shire North American Group Inc | 2 | $26 |
| Amgen | 2 | $25 |
| Radius Health, Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
| Companion Medical, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synthroid$2,250
- t:slim X2 insulin pump$300
- MINIMED 780G$157
- Omnipod$131
- NEXLIZET$125
- NEXLETOL$125
- Yorvipath$125
- FreeStyle Libre$124
- PRALUENT$111
- Wegovy$108
How this compares
$4,735 in reported general payments places this provider in the 55th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 135 | $206,306 |
| TrulicityDulaglutide | 86 | $183,617 |
| MounjaroTirzepatide | 131 | $175,670 |
| JardianceEmpagliflozin | 63 | $106,241 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $56,804 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $48,271 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $46,663 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $21,116 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $18,765 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $14,239 |
| Novolog FlexpenInsulin Aspart | 45 | $14,224 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $13,268 |
| SynthroidLevothyroxine Sodium | 77 | $7,232 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $6,455 |
| VascepaIcosapent Ethyl | 12 | $6,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $256 | $359,287217 claims |
| Novo NordiskOzempic, Novolog | $310 | $212,221152 claims |
| Boehringer IngelheimJardiance | $11 | $106,24163 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $266 | $46,66332 claims |
| AbbVieSynthroid | $2,320 | $7,23277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Louisville
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Mehdi PoorkayLouisville$81K
- Angelino YsonLouisville$15K
- Mary SelfLouisville$14K
- Omolara FakunleLouisville$13K
- Kaitlyn TuckerLouisville$9K
- Manikya KuritiLouisville$7K
- Swapna DeoLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.